Cardiac Computed Tomography Angiographic Findings as Predictors of Late Heart Failure in an Asymptomatic Diabetic Cohort: An 8-Year Prospective Follow-Up StudyHalon D.A.a-c · Ayman J.a · Rubinshtein R.a, c · Zafrir B.a · Azencot M.a · Lewis B.S.b, c
aDepartment of Cardiovascular Medicine and bCardiovascular Clinical Trials Institute, Lady Davis Carmel Medical Center, and cRuth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Objectives: Predictive models for heart failure (HF) in heterogeneous populations have had limited success. We examined cardiac computed tomography angiography (CTA) predictors of HF or cardiovascular death (HF-CVD) in a prospective study of asymptomatic diabetics undergoing baseline assessment by CTA. Methods: The subjects (n = 735, aged 55-74 years, 51.2% women) had no clinical history of cardiovascular disease at study entry. Coronary artery calcium (CAC) score, CTA-defined coronary atherosclerosis, cardiac chamber volumes, and clinical data were collected and late outcome events recorded over 8.4 ± 0.6 years (range 7.3-9.3). Results: HF-CVD occurred in 41 (5.6%) subjects, with HF occurring mostly (19/23, 82.6%) in subjects without preceding myocardial infarction. Baseline univariate clinical outcome predictors of HF-CVD included older age (p = 0.027), the duration of diabetes (p = 0.004), HbA1c (p < 0.0001), microvascular disease (retinopathy, microalbuminuria) (p < 0.0001), and systolic blood pressure (p = 0.035). Baseline univariate CTA predictors included CAC score (p = 0.004), coronary stenosis (p = 0.047), and a CTA-defined left/right atrial (LA/RA) volume ratio >1 (p < 0.0001). Independent predictors were an LA/RA volume ratio >1, microvascular disease, and systolic blood pressure (model C-statistic 0.792, 95% CI 0.758-0.824). Measures of the extent of coronary artery disease (CAD) were not independent predictors of HF-CVD. Conclusions: In a low- to moderate-risk asymptomatic diabetic population, CTA LA enlargement (LA/RA volume ratio) but not the extent of CAD had independent prognostic value for HF-CVD in addition to the clinical variables.
© 2017 S. Karger AG, Basel
- Cavender MA, Steg PG, Smith SC, Eagle K, Ohman EM, Goto S, et al: Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of atherothrombosis for continued health (REACH) registry. Circulation 2015;132:923-931.
- Johansson I, Dahlström U, Edner M, Näsman P, Rydén L, Norhammar A: Prognostic implications of type 2 diabetes mellitus in ischemic and nonischemic heart failure. J Am Coll Cardiol 2016;68:1404-1416.
- Das SR, Drazner MH, Yancy CW, Stevenson LW, Gersh BJ, Dries DL: Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial. Am Heart J 2004;148:883-888.
- Wang CCL, Hess CN, Hiatt WR, Goldfine AB: Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation 2016;133:2459-2502.
- McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al: Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.
- Sciarretta S, Palano F, Tocci G, Baldini R, Volpe M: Antihypertensive treatment and development of heart failure in hypertension. Arch Intern Med 2011;171:384-394.
- Kumar R, Kerins DM, Walther T: Cardiovascular safety of anti-diabetic drugs. Eur Hear J Cardiovasc Pharmacother 2016;2:32-43.
- Fitchett DH, Udell JA, Inzucchi SE: Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Eur J Heart Fail 2017;19:43-53.
- Allen LA, Matlock DD, Shetterly SM, Xu S, Levy WC, Portalupi LB, et al: Use of risk models to predict death in the next year among individual ambulatory patients with heart failure. JAMA Cardiol 2017;2:435-441.
- Halon DA, Azencot M, Rubinshtein R, Zafrir B, Flugelman MY, Lewis BS: Coronary computed tomography (CT) angiography as a predictor of cardiac and noncardiac vascular events in asymptomatic type 2 diabetics: a 7‐year population‐based cohort study. J Am Heart Assoc 2016;5:e003226.
- Gensini GG: A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983;51:606.
- van Melle JP, Bot M, De Jonge P, De Boer RA, van Veldhuisen DJ, Whooley MA: Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the Heart and Soul Study. Diabetes Care 2010;33:2084-2089.
- Kajimoto K, Minami Y, Sato N, Kasanuki H: Etiology of heart failure and outcomes in patients hospitalized for acute decompensated heart failure with preserved or reduced ejection fraction. Am J Cardiol 2016;118:1881-1887.
- Poulsen MK, Dahl JS, Henriksen JE, Hey TM, Høilund-Carlsen PF, Beck-Nielsen H, et al: Left atrial volume index: relation to long-term clinical outcome in type 2 diabetes. J Am Coll Cardiol 2013;62:2416-2421.
- Ouwerkerk W, Voors AA, Zwinderman AH: Factors influencing the predictive power of models for predicting mortality and/or heart-failure hospitalization in patients with heart failure. JACC Heart Fail 2014;2:429-436.
- Arques S, Jaubert MP, Bonello L, Sbragia P, Nicoud A, Paganelli F: Usefulness of left atrial volume for the diagnosis of diastolic heart failure: an echocardiographic-catheterization study. Int J Cardiol 2010;144:317-319.
- Lim TK, Dwivedi G, Hayat S, Majumdar S, Senior R: Independent value of left atrial volume index for the prediction of mortality in patients with suspected heart failure referred from the community. Heart 2009;95:1172-1178.
- Pritchett AM, Mahoney DW, Jacobsen SJ, Rodeheffer RJ, Karon BL, Redfield MM: Diastolic dysfunction and left atrial volume: a population-based study. J Am Coll Cardiol 2005;45:87-92.
- Blomstrand P, Engvall M, Festin K, Lindström T, Länne T, Maret E, et al: Left ventricular diastolic function, assessed by echocardiography and tissue Doppler imaging, is a strong predictor of cardiovascular events, superior to global left ventricular longitudinal strain, in patients with type 2 diabetes. Eur Heart J Cardiovasc Imaging 2015;16:1000-1007.
- Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, et al: Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail 2015;3:136-145.
- Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, et al: Glycemic control and heart failure among adult patients with diabetes. Circulation 2001;103:2668-2673.
- Seferović PM, Paulus WJ: Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J 2015;36:1718-1727.
- Kawata T, Daimon M, Miyazaki S, Ichikawa R, Maruyama M, Chiang S-J, et al: Coronary microvascular function is independently associated with left ventricular filling pressure in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2015;14:98.
- Bonapace S, Rossi A, Lipari P, Bertolini L, Zenari L, Lanzoni L, et al: Relationship between increased left atrial volume and microvascular complications in patients with type 2 diabetes. J Diabetes Complications 2015;29:822-828.
- Diabetes Prevention Program Research Group: Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol 2015;3:866-875.
- Lind M, Olsson M, Rosengren a, Svensson a-M, Bounias I, Gudbjörnsdottir S: The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia 2012;55:2946-2953.
- Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128.
- Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S: Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-588.
- Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al: Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 2016;37:1671-1680.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.